BioNTech SE (ETR:22UA)
91.40
-3.40 (-3.59%)
At close: Apr 23, 2026
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
€367,606
Profits / Employee
€145,523
Market Cap
22.79B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 178,583 |
| Fresenius Medical Care AG | 109,698 |
| Bayer Aktiengesellschaft | 87,280 |
| Siemens Healthineers AG | 73,800 |
| Merck KGaA | 59,077 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 14,042 |
| Ottobock SE & Co. KGaA | 10,365 |
BioNTech SE News
- 2 days ago - Two experimental drugs showed striking early results against pancreatic cancer - WSJ
- 2 days ago - BioNTech (BNTX) Gains Investor Interest Following Promising ASCO Presentation - GuruFocus
- 2 days ago - BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026 - GlobeNewsWire
- 8 days ago - 2 Healthcare Stocks to Buy and 1 to Approach With Caution - The Motley Fool
- 10 days ago - BioNTech Reports Phase 1/2a Study Data For BNT323/DB-1303 In HER2-Expressing Endometrial Cancer - Nasdaq
- 11 days ago - BioNTech (BNTX) Reports Encouraging Phase 2 Results for Cancer Treatment - GuruFocus
- 12 days ago - BioNTech SE: BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - Finanz Nachrichten
- 12 days ago - BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - GlobeNewsWire